Outcome of listing for cardiac transplantation for failed Fontan

A multi-institutional study

D. Bernstein, D. Naftel, C. Chin, L. J. Addonizio, P. Gamberg, E. D. Blume, Daphne T. Hsu, C. E. Canter, J. K. Kirklin, W. R. Morrow

Research output: Contribution to journalArticle

171 Citations (Scopus)

Abstract

BACKGROUND - The Fontan procedure is a successful palliation for children with single-ventricle physiology; however, many will eventually require heart transplantation. The purpose of this study was to determine risk factors for death awaiting transplantation and to examine results after transplantation in Fontan patients. METHODS AND RESULTS - A retrospective, multi-institutional review was performed of 97 Fontan patients <18 years of age listed at 17 Pediatric Heart Transplant Study centers from 1993 to 2001. Mean age at listing was 9.7 years (0.5 to 17.9 years); 25% were <4 years old; 53% were United Network for Organ Sharing status 1; 18% required ventilator support. Pretransplantation survival was 78% at 6 months and 74% at 12 months and was similar to 243 children with other congenital heart disease (CHD) and 747 children without congenital heart disease (No-CHD), who were also awaiting transplantation. Patients who were younger, status 1, had shorter interval since Fontan, or were on a ventilator were more likely to die while waiting. At 6 months, the probability of receiving a transplant was similar for status 1 and 2 (65% versus 68%); however, the probability of death was higher for status 1 (22% versus 5%). Seventy patients underwent transplantation. Survival was 76% at 1 year, 70% at 3 years, and 68% at 5 years, slightly less than CHD and No-CHD patients. Causes of death included infection (30%), graft failure (17%), rejection (13%), sudden death (13%), and graft coronary artery disease (9%). Protein-losing enteropathy (present in 34 patients) resolved in all who survived >30 days after transplantation. CONCLUSIONS - Heart transplantation is an effective therapy for pediatric patients with a failed Fontan. Although early posttransplantation survival is slightly lower than other patients with CHD, long-term results are encouraging, and protein-losing enteropathy can be expected to resolve.

Original languageEnglish (US)
Pages (from-to)273-280
Number of pages8
JournalCirculation
Volume114
Issue number4
DOIs
StatePublished - Jul 2006
Externally publishedYes

Fingerprint

Heart Transplantation
Transplantation
Protein-Losing Enteropathies
Fontan Procedure
Pediatrics
Survival
Therapeutics

Keywords

  • Cardiomyopathies
  • Heart defects, congenital
  • Heart failure, congestive
  • Heart transplantation
  • Protein-losing enteropathies

ASJC Scopus subject areas

  • Physiology
  • Cardiology and Cardiovascular Medicine

Cite this

Bernstein, D., Naftel, D., Chin, C., Addonizio, L. J., Gamberg, P., Blume, E. D., ... Morrow, W. R. (2006). Outcome of listing for cardiac transplantation for failed Fontan: A multi-institutional study. Circulation, 114(4), 273-280. https://doi.org/10.1161/CIRCULATIONAHA.105.548016

Outcome of listing for cardiac transplantation for failed Fontan : A multi-institutional study. / Bernstein, D.; Naftel, D.; Chin, C.; Addonizio, L. J.; Gamberg, P.; Blume, E. D.; Hsu, Daphne T.; Canter, C. E.; Kirklin, J. K.; Morrow, W. R.

In: Circulation, Vol. 114, No. 4, 07.2006, p. 273-280.

Research output: Contribution to journalArticle

Bernstein, D, Naftel, D, Chin, C, Addonizio, LJ, Gamberg, P, Blume, ED, Hsu, DT, Canter, CE, Kirklin, JK & Morrow, WR 2006, 'Outcome of listing for cardiac transplantation for failed Fontan: A multi-institutional study', Circulation, vol. 114, no. 4, pp. 273-280. https://doi.org/10.1161/CIRCULATIONAHA.105.548016
Bernstein, D. ; Naftel, D. ; Chin, C. ; Addonizio, L. J. ; Gamberg, P. ; Blume, E. D. ; Hsu, Daphne T. ; Canter, C. E. ; Kirklin, J. K. ; Morrow, W. R. / Outcome of listing for cardiac transplantation for failed Fontan : A multi-institutional study. In: Circulation. 2006 ; Vol. 114, No. 4. pp. 273-280.
@article{65099a8f28d747e9a11c4eae3797018d,
title = "Outcome of listing for cardiac transplantation for failed Fontan: A multi-institutional study",
abstract = "BACKGROUND - The Fontan procedure is a successful palliation for children with single-ventricle physiology; however, many will eventually require heart transplantation. The purpose of this study was to determine risk factors for death awaiting transplantation and to examine results after transplantation in Fontan patients. METHODS AND RESULTS - A retrospective, multi-institutional review was performed of 97 Fontan patients <18 years of age listed at 17 Pediatric Heart Transplant Study centers from 1993 to 2001. Mean age at listing was 9.7 years (0.5 to 17.9 years); 25{\%} were <4 years old; 53{\%} were United Network for Organ Sharing status 1; 18{\%} required ventilator support. Pretransplantation survival was 78{\%} at 6 months and 74{\%} at 12 months and was similar to 243 children with other congenital heart disease (CHD) and 747 children without congenital heart disease (No-CHD), who were also awaiting transplantation. Patients who were younger, status 1, had shorter interval since Fontan, or were on a ventilator were more likely to die while waiting. At 6 months, the probability of receiving a transplant was similar for status 1 and 2 (65{\%} versus 68{\%}); however, the probability of death was higher for status 1 (22{\%} versus 5{\%}). Seventy patients underwent transplantation. Survival was 76{\%} at 1 year, 70{\%} at 3 years, and 68{\%} at 5 years, slightly less than CHD and No-CHD patients. Causes of death included infection (30{\%}), graft failure (17{\%}), rejection (13{\%}), sudden death (13{\%}), and graft coronary artery disease (9{\%}). Protein-losing enteropathy (present in 34 patients) resolved in all who survived >30 days after transplantation. CONCLUSIONS - Heart transplantation is an effective therapy for pediatric patients with a failed Fontan. Although early posttransplantation survival is slightly lower than other patients with CHD, long-term results are encouraging, and protein-losing enteropathy can be expected to resolve.",
keywords = "Cardiomyopathies, Heart defects, congenital, Heart failure, congestive, Heart transplantation, Protein-losing enteropathies",
author = "D. Bernstein and D. Naftel and C. Chin and Addonizio, {L. J.} and P. Gamberg and Blume, {E. D.} and Hsu, {Daphne T.} and Canter, {C. E.} and Kirklin, {J. K.} and Morrow, {W. R.}",
year = "2006",
month = "7",
doi = "10.1161/CIRCULATIONAHA.105.548016",
language = "English (US)",
volume = "114",
pages = "273--280",
journal = "Circulation",
issn = "0009-7322",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Outcome of listing for cardiac transplantation for failed Fontan

T2 - A multi-institutional study

AU - Bernstein, D.

AU - Naftel, D.

AU - Chin, C.

AU - Addonizio, L. J.

AU - Gamberg, P.

AU - Blume, E. D.

AU - Hsu, Daphne T.

AU - Canter, C. E.

AU - Kirklin, J. K.

AU - Morrow, W. R.

PY - 2006/7

Y1 - 2006/7

N2 - BACKGROUND - The Fontan procedure is a successful palliation for children with single-ventricle physiology; however, many will eventually require heart transplantation. The purpose of this study was to determine risk factors for death awaiting transplantation and to examine results after transplantation in Fontan patients. METHODS AND RESULTS - A retrospective, multi-institutional review was performed of 97 Fontan patients <18 years of age listed at 17 Pediatric Heart Transplant Study centers from 1993 to 2001. Mean age at listing was 9.7 years (0.5 to 17.9 years); 25% were <4 years old; 53% were United Network for Organ Sharing status 1; 18% required ventilator support. Pretransplantation survival was 78% at 6 months and 74% at 12 months and was similar to 243 children with other congenital heart disease (CHD) and 747 children without congenital heart disease (No-CHD), who were also awaiting transplantation. Patients who were younger, status 1, had shorter interval since Fontan, or were on a ventilator were more likely to die while waiting. At 6 months, the probability of receiving a transplant was similar for status 1 and 2 (65% versus 68%); however, the probability of death was higher for status 1 (22% versus 5%). Seventy patients underwent transplantation. Survival was 76% at 1 year, 70% at 3 years, and 68% at 5 years, slightly less than CHD and No-CHD patients. Causes of death included infection (30%), graft failure (17%), rejection (13%), sudden death (13%), and graft coronary artery disease (9%). Protein-losing enteropathy (present in 34 patients) resolved in all who survived >30 days after transplantation. CONCLUSIONS - Heart transplantation is an effective therapy for pediatric patients with a failed Fontan. Although early posttransplantation survival is slightly lower than other patients with CHD, long-term results are encouraging, and protein-losing enteropathy can be expected to resolve.

AB - BACKGROUND - The Fontan procedure is a successful palliation for children with single-ventricle physiology; however, many will eventually require heart transplantation. The purpose of this study was to determine risk factors for death awaiting transplantation and to examine results after transplantation in Fontan patients. METHODS AND RESULTS - A retrospective, multi-institutional review was performed of 97 Fontan patients <18 years of age listed at 17 Pediatric Heart Transplant Study centers from 1993 to 2001. Mean age at listing was 9.7 years (0.5 to 17.9 years); 25% were <4 years old; 53% were United Network for Organ Sharing status 1; 18% required ventilator support. Pretransplantation survival was 78% at 6 months and 74% at 12 months and was similar to 243 children with other congenital heart disease (CHD) and 747 children without congenital heart disease (No-CHD), who were also awaiting transplantation. Patients who were younger, status 1, had shorter interval since Fontan, or were on a ventilator were more likely to die while waiting. At 6 months, the probability of receiving a transplant was similar for status 1 and 2 (65% versus 68%); however, the probability of death was higher for status 1 (22% versus 5%). Seventy patients underwent transplantation. Survival was 76% at 1 year, 70% at 3 years, and 68% at 5 years, slightly less than CHD and No-CHD patients. Causes of death included infection (30%), graft failure (17%), rejection (13%), sudden death (13%), and graft coronary artery disease (9%). Protein-losing enteropathy (present in 34 patients) resolved in all who survived >30 days after transplantation. CONCLUSIONS - Heart transplantation is an effective therapy for pediatric patients with a failed Fontan. Although early posttransplantation survival is slightly lower than other patients with CHD, long-term results are encouraging, and protein-losing enteropathy can be expected to resolve.

KW - Cardiomyopathies

KW - Heart defects, congenital

KW - Heart failure, congestive

KW - Heart transplantation

KW - Protein-losing enteropathies

UR - http://www.scopus.com/inward/record.url?scp=33748062962&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748062962&partnerID=8YFLogxK

U2 - 10.1161/CIRCULATIONAHA.105.548016

DO - 10.1161/CIRCULATIONAHA.105.548016

M3 - Article

VL - 114

SP - 273

EP - 280

JO - Circulation

JF - Circulation

SN - 0009-7322

IS - 4

ER -